secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001104659-25-122353
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics reports positive exploratory endpoint from Phase 1b study of GT-02287 in Parkinson's Disease
--------------------------------------------------------------------------------

- GT-02287 reduced elevated GluSph in CSF to near-normal levels after 90 days in Phase 1b study.
- 19 of 21 enrolled participants completed 90-day dosing; 15 (79%) chose to continue in 9-month extension ending Sept 2026.
- Drug well-tolerated; data monitoring committee recommended study continue with no changes.
- Company has capital to fund operations through end of Phase 1b extension and year-end 2026.
- Phase 1 healthy volunteer study showed favorable safety, target engagement with increased GCase activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925122353/0001104659-25-122353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925122353/tm2533810d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-122353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer